Skip to main content
LGND
NASDAQ Life Sciences

Ligand Buys Ryjunea Royalty Rights for $23M, Adding First Approved Pediatric Myopia Drug

Tom Rudovsky · Reported by GlobeNewswire
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
8
Price
$290
Mkt Cap
$5.783B
52W Low
$163.45
52W High
$326.63
52W Position info
77% above low
Off High info
11% below high
Rel. Volume info
0.7× avg
Market data snapshot near publication time

LGND sits 77% above its 52-week low of $163.45.

Summary

Ligand acquired a tiered royalty interest in Santen's Ryjunea from Sydnexis for $23 million upfront. The deal gives Ligand a low-double-digit to high-teens royalty on Ryjunea net sales in Europe, the Middle East, and Africa, plus milestone payments. Ryjunea is the first and only approved pharmacological treatment for pediatric myopia in the EU and UK, addressing a large and growing market. This adds a differentiated, commercial-stage asset to Ligand's royalty portfolio, which already spans over 200 assets following the XOMA acquisition. The modest upfront cost relative to Ligand's market cap and the product's first-mover status make this a meaningful portfolio addition.

At the time of this announcement, LGND was trading at $290.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $5.8B. The 52-week trading range was $163.45 to $326.63. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.


Price Chart

Share this article

Copied!

LGND - Latest Insights

LGND
Oct 30, 2026, 4:47 PM EDT
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $324.00
Real-time Price: $304.60 info
Change: -$19.40 (-6%) info
Market Cap: $6.106B info
LGND
Oct 29, 2026, 3:12 PM EDT
Source: Reuters
Importance Score:
7
Price at Filing: $316.21
Real-time Price: $304.60 info
Change: -$11.61 (-4%) info
Market Cap: $6.106B info
LGND
Oct 29, 2026, 7:14 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $311.87
Real-time Price: $304.60 info
Change: -$7.27 (-2%) info
Market Cap: $6.106B info
LGND
Oct 29, 2026, 7:00 AM EDT
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $311.87
Real-time Price: $304.60 info
Change: -$7.27 (-2%) info
Market Cap: $6.106B info
LGND
Sep 24, 2026, 7:15 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $298.41
Real-time Price: $304.60 info
Change: +$6.19 (+2%) info
Market Cap: $6.106B info